merck glp 1 agonist GLP-1 Agonists: A Comprehensive Overview Merck Enters into Exclusive Global
Description
doi: 10.2337/db25-0158
Furthermore, emerging evidence suggests that GLP-1 receptor agonists may lower the risk of obesity-related cancers
Their effects often emerge only in specific physiological contexts, such as exercise, growth, or aging, and may depend on coordinated signaling across multiple tissues
Interestingly, the reduction in HbA1c was already evident after the first 4 weeks of treatment and remained statistically significant up to the end of the 52-week observation period, supporting the evidence of rapid efficacy of the drug and great durability, which was independent from weight loss
It is important to consider the timing of a switch between treatments
